Immunotherapies such as chimeric antigen receptor (CAR) T cell therapy show a lot of promise to treat patients with various types of cancer. Developing a successful immunotherapy is challenging because patients show variable response rates and can develop therapy-induced toxicity or resistance. Recent technological advances now allow researchers to profile immune and cancer cell responses at the single-cell level, which helps them better understand the mechanisms underlying heterogeneous immunotherapy responses.
Download this research highlight from 10x Genomics to discover recent breakthroughs in CAR T therapeutic development.
